Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Amphetamine+ SPD503 · 1 trial · 1 indication
Change in the Attention Deficit Hyperactivity Disorder Rating Scale-fourth edition (ADHD-RS-IV) total score from baseline. The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.
| Arm | Type | Description |
|---|---|---|
| Methylphenidate + SPD503 | EXPERIMENTAL | - |
| Amphetamine + SPD503 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Methylphenidate + SPD503 (Guanfacine hydrochloride) | DRUG | - |
| Amphetamine + SPD503 | DRUG | - |
Inclusion Criteria: * Subjects with a primary diagnosis of ADHD * Subject on a stable dose of a psychostimulant approved for the treatment of ADHD for at least 1 month, with sub-optimal control in the Investigator's opinion * Male or non-pregnant female subject who agrees to comply with any applica...
Amphetamine+ SPD503 is an investigational small molecule being studied for attention deficit disorder with hyperactivity (ADHD). It is being developed by Takeda Pharmaceutical Company Limited (TAK) and is currently in Phase 2 clinical development. The drug is intended for use in children and adolescents aged 6 to 17 years.
Amphetamine+ SPD503 is a small molecule that contains amphetamine, a central nervous system stimulant. It is being studied for its effects on attention deficit disorder with hyperactivity (ADHD). The specific molecular target of the drug has not been disclosed in the available information.
Amphetamine+ SPD503 is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker symbol TAK. The drug is currently in Phase 2 clinical development for attention deficit disorder with hyperactivity (ADHD).
Amphetamine+ SPD503 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 clinical trial has been completed, and the drug is being studied for attention deficit disorder with hyperactivity (ADHD).
Amphetamine+ SPD503 has one completed clinical trial, NCT00151996, which was a Phase 2 study titled 'Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD).' The trial enrolled 75 participants and was controlled but not randomized or double-blind.